Can removing the prostate boost drug therapy in advanced cancer?

NCT ID NCT06306612

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This trial is testing whether adding surgery to remove the prostate to standard drug therapy helps men with advanced, hormone-sensitive prostate cancer that has spread to multiple sites. Participants will receive either the usual drug treatment alone or the same drugs plus surgery. The study aims to see if the combined approach delays cancer progression and improves survival compared to standard care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Combination of chemotherapy (docetaxel), hormone therapy (darolutamide), and surgery to remove the prostate (cytoreductive prostatectomy)
What this could lead to
If successful, this could establish a new treatment approach that delays cancer progression and improves survival for men with advanced prostate cancer.
What could go wrong
The trial is early and not yet proven; surgery plus drugs may not improve outcomes over standard care and could carry added risks from the operation and stronger side effects from combined treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DE NOVO POLY-METASTATIC HORMONE SENSITIVE PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Renji Hospital, Shanghai Jiao Tong University School of Medicine

    RECRUITING

    Shanghai, Shanghai Municipality, 200127, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.